Results 91 to 100 of about 27,196 (258)

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation

open access: yesFrontiers in Immunology
BackgroundImmune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due to reduced T cell activity.
Oana Hangiu   +27 more
doaj   +1 more source

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI‐SAFRADJU‐2501)

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus   +60 more
wiley   +1 more source

High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose

open access: yesFluids and Barriers of the CNS
Background Transferrin receptor (TfR)-mediated transcytosis is a well-established method for delivering biologic therapeutics and diagnostics to the brain.
Gillian Bonvicini   +9 more
doaj   +1 more source

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

open access: yesiNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu   +5 more
wiley   +1 more source

A mechanistic quantitative systems pharmacology model platform for translational efficacy evaluation and checkpoint combination design of bispecific immuno-modulatory antibodies

open access: yesFrontiers in Pharmacology
Over the past 2 decades, tumor immunotherapies have witnessed remarkable advancements, especially with the emergence of immune checkpoint-targeting bispecific antibodies.
Yiyang Xu   +9 more
doaj   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

open access: yesiNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid   +4 more
wiley   +1 more source

Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae

open access: yesInterdisciplinary Medicine, EarlyView.
A novel immunization strategy using a low‐virulence, multidrug‐resistant strain yields synergistic monoclonal antibodies against hypervirulent Klebsiella pneumoniae. These antibodies provide cross‐serotype protection through a dual‐mechanism of pathogen clearance and immunomodulation, offering a promising non‐antibiotic therapeutic for resistant ...
Yushan Jiang   +10 more
wiley   +1 more source

A novel single-vector featuring bidirectional promoters for production of bispecific antibody against rabies virus

open access: yesBMC Biotechnology
Background The World Health Organization (WHO) recommends combination therapy with two non-overlapping monoclonal antibodies (mAbs) to enhance protection in Rabies post-exposure prophylaxis (PEP).
Zhigao Zhang   +4 more
doaj   +1 more source

c‐Met‐Targeted Imaging Agents: Progress and Challenges

open access: yesiRADIOLOGY, EarlyView.
This review summarizes recent advances in c‐Met‐targeted imaging probes, including hepatocyte growth factor (HGF) ligands, antibodies, peptides, and small molecules across magnetic resonance imaging (MRI), positron emission tomography (PET), single‐photon emission computed tomography (SPECT), and optical imaging modalities.
Yonghao Li   +4 more
wiley   +1 more source

Chemical-Assembled Macrophage-Engaging Glypican-3 × Signal Regulatory Protein-α (SIRP-α) Bispecific Antibody for Immunotherapy Against Liver Cancer. [PDF]

open access: yesMedComm (2020)
We developed a novel chemical strategy to generate a glypican‐3 × SIRP‐α bispecific antibody that simultaneously blocks the CD47 “don't eat me” signal, engages macrophages to target liver cancer cells for enhanced phagocytosis, and antigen presentation. This novel combination of targets demonstrates remarkable efficacy in vitro and in vivo.
Tang B   +14 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy